The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of durvalumab plus carboplatin and etoposide for patients with previously untreated extensive-stage small-cell lung cancer (ES-SCLC) with a poor performance status: The results from phase II single-arm study (NEJ045A study).
 
Yu Saida
Speakers' Bureau - AstraZeneca; Chugai Pharma; Lilly; Takeda
 
Tetsuhiko Asao
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Merck; MSD K.K; Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Satoshi Watanabe
Consulting or Advisory Role - Novartis
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Nippon Kayaku
 
Akira Kisohara
No Relationships to Disclose
 
Kazuma Kishi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst)
 
Ryo Morita
Consulting or Advisory Role - Daiichi Sankyo
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly
 
Taku Nakagawa
Honoraria - AstraZeneca; Chugai Pharma; Japan Blood Products Organization; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Yoko Tsukita
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly; MSD; Nippon Boehringer Ingelheim; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca
Research Funding - Chugai Pharma (Inst); Lilly (Inst)
 
Naoki Furuya
No Relationships to Disclose
 
Taichi Miyawaki
No Relationships to Disclose
 
Nobuhisa Ishikawa
No Relationships to Disclose
 
Tadaaki Yamada
Speakers' Bureau - Chugai Pharma; Lilly
Research Funding - AstraZeneca; Janssen; Ono Pharmaceutical; Pfizer; Takeda
 
Takahiro Tanaka
No Relationships to Disclose
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Company; Chugai Pharma; Eisai; Lilly Japan; MSD K.K.; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer
Research Funding - Eisai (Inst)
 
Toshiaki Kikuchi
Consulting or Advisory Role - Janssen
Speakers' Bureau - AstraZeneca; Kyorin; Nippon Boehringer Ingelheim
Research Funding - Chugai Pharma; Nobelpharma; Shionogi
 
Makoto Maemondo
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi-Sankyo; Lilly; Merck Sharp and Dohme; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Ono Pharmaceutical
Speakers' Bureau - AstraZeneca
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Boehringer Ingelheim (Inst); Chugai Pharma; Janssen (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kunihiko Kobayashi
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan
Speakers' Bureau - AstraZeneca
Research Funding - Zeria Pharmaceutical Co. (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on Japanese patent # 7422498; Peptide of inhibiting cell migration, cell invasion, and cancer metastasis.